Last ¥1,120 JPY
Change Today +8.00 / 0.72%
Volume 274.6K
4576 On Other Exchanges
Symbol
Exchange
Tokyo
Berlin
As of 1:00 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

d.western therapeutics insti (4576) Snapshot

Open
¥1,108
Previous Close
¥1,112
Day High
¥1,127
Day Low
¥1,091
52 Week High
08/19/14 - ¥3,550
52 Week Low
02/4/14 - ¥552.00
Market Cap
25.5B
Average Volume 10 Days
368.6K
EPS TTM
¥-9.25
Shares Outstanding
22.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for D.WESTERN THERAPEUTICS INSTI (4576)

Related News

No related news articles were found.

d.western therapeutics insti (4576) Related Businessweek News

No Related Businessweek News Found

d.western therapeutics insti (4576) Details

D. Western Therapeutics Institute, Inc., a biotechnology company, discovers and develops new drugs to serve patients worldwide. The company is developing K-134, an anti-platelet drug, which is in Phase IIb clinical trial for the treatment of arteriosclerosis obliterans; K-115, an anti-glaucoma drug for glaucoma and ocular hypertension treatment, which has completed Phase III clinical trial; and H-1129, an anti-glaucoma drug. Its discovery stage products include anti-glaucoma, central nervous system, cardiovascular system, and respiratory system drugs, as well as ophthalmology and related area. The company was founded in 1999 and is headquartered in Nagoyashi, Japan.

13 Employees
Last Reported Date: 03/27/14
Founded in 1999

d.western therapeutics insti (4576) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

d.western therapeutics insti (4576) Key Developments

D.Western Therapeutics Institute, Inc. Launches Drug for Treating Glaucoma and Ocular Hypertension

D.Western Therapeutics Institute, Inc. announced that the company have received notice from the licensee, Kowa Company Ltd. inhibitor the company have developed, GLANATEC ophthalmic solution 0.4% (nonproprietary name: ripasudil hydrochloride hydrate; development name: K-115; hereinafter called "this product"), has been launched. This product is a therapeutic drug for glaucoma and ocular hypertension with the world's first mechanism of action, which stimulates the drainage of aqueous humor from the main outflow tract via the trabecular meshwork and Schlemm's canal by inhibiting Rho kinase, resulting in a decreasing ocular pressure. In the clinical studies in patients with primary open angle glaucoma and ocular hypertension conducted in Japan, this product demonstrated the effect of decreasing ocular pressure both in monotherapy and in combination with an existing drug for treating glaucoma and ocular hypertension.

D.Western Therapeutics Institute, Inc. - Shareholder/Analyst Call

D.Western Therapeutics Institute, Inc. - Shareholder/Analyst Call

D.Western Therapeutics Institute, Inc. to Report Q3, 2014 Results on Nov 13, 2014

D.Western Therapeutics Institute, Inc. announced that they will report Q3, 2014 results at 3:30 PM, Tokyo Standard Time on Nov 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4576:JP ¥1,120.00 JPY +8.00

4576 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4576.
View Industry Companies
 

Industry Analysis

4576

Industry Average

Valuation 4576 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 334.2x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 304.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact D.WESTERN THERAPEUTICS INSTI, please visit www.dwti.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.